How a Drug Company Made $114 Billion by Gaming the U.S. Patent System


AbbVie for years delayed competition for its blockbuster drug Humira, at the expense of patients and taxpayers. The monopoly is about to end.

Previous Story

Netherlands and Japan Said to Join U.S. in Curbing China’s Access to Chip Tech

Next Story

Johnson & Johnson’s Talc-Related Bankruptcy Filing Is Rejected